Helus Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
36.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$3.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| HLP003 Phase 3 APPROACH Topline Data Readout | 20 Nov 2026 |
Monitoring Framework
Key Performance Indicators
APPROACH Phase 3 Trial Enrollment Quarterly223.0Target: 223 (Completed)
Cash Balance (USD) Quarterly157.3MTarget: Sufficient runway into 2027
Watch Items
- HLP003 Phase 3 APPROACH Topline Data ReadoutTrigger: Mid-to-third week of November 2026Action: Evaluate primary endpoint (MADRS score change at 6 weeks) and secondary endpoint (12 weeks) to support potential FDA NDA filing in 2028.
- HLP004 Phase 2 GAD Dosing and Regulatory AlignmentTrigger: FDA alignment on acceptable development program by end of 2026Action: Resolve dosing questions raised by Phase 2 data (where 2 mg and 20 mg doses showed similar efficacy but different hallucination rates) to finalize Phase 3 trial design.
- Permanent CEO AppointmentTrigger: Board announcement of a permanent successor to Michael ColaAction: Assess the strategic direction and commercialization experience of the new executive leadership.
Research as of 24 Jul 2026